Maytansine

"Maytansine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An ansa macrolide isolated from the MAYTENUS genus of East African shrubs.

Descriptor ID	D008453
MeSH Number(s)	D02.540.505.495 D04.345.295.500
Concept/Terms	Maytansine Maytansine Maitansine Maytansinoid DM1 Maytansinoid DM1 DM1, Maytansinoid Mertansine Emtansine Maytansinoid DM4 Maytansinoid DM4 DM4, Maytansinoid Soravtansine Ravtansine

Below are MeSH descriptors whose meaning is more general than "Maytansine".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Lactones [D02.540]
Macrolides [D02.540.505]
Maytansine [D02.540.505.495]
Polycyclic Compounds [D04]
Macrocyclic Compounds [D04.345]
Lactams, Macrocyclic [D04.345.295]
Maytansine [D04.345.295.500]

Below are MeSH descriptors whose meaning is related to "Maytansine".

Below are MeSH descriptors whose meaning is more specific than "Maytansine".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Maytansine" by people in this website by year, and whether "Maytansine" was a major or minor topic of these publications.

Bar chart showing 4 publications over 4 distinct years, with a maximum of 1 publications in 2020 and 2022 and 2023 and 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Total
2020	1	1
2022	1	1
2023	1	1
2024	1	1

Below are the most recent publications written about "Maytansine" by people in Profiles.

O'Malley DM, Myers T, Wimberger P, Van Gorp T, Redondo A, Cibula D, Nicum S, Rodrigues M, Backes FJ, Barlin JN, Lewin SN, Lim P, Pothuri B, Diver E, Banerjee S, Lorusso D. Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRa-high platinum-sensitive ovarian cancer. Future Oncol. 2024; 20(32):2423-2436.

View in: PubMed
Moore KN, Angelergues A, Konecny GE, Garc?a Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Est?vez-Garc?a P, Coffman L, Nicum S, Duska LR, Pignata S, G?lvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T. Mirvetuximab Soravtansine in FRa-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023 12 07; 389(23):2162-2174.

View in: PubMed
Perez EA, Dang C, Lee C, Singh J, Wang K, Layton JB, Gilsenan A, Hackshaw MD, Cortes J. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review. Breast Cancer Res Treat. 2022 Jul; 194(1):1-11.

View in: PubMed
Canakci M, Singh K, Munkhbat O, Shanthalingam S, Mitra A, Gordon M, Osborne BA, Thayumanavan S. Targeting CD4+ Cells with Anti-CD4 Conjugated Mertansine-Loaded Nanogels. Biomacromolecules. 2020 06 08; 21(6):2473-2481.

View in: PubMed
Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011 Feb 01; 29(4):398-405.

View in: PubMed
Liu C, Tadayoni BM, Bourret LA, Mattocks KM, Derr SM, Widdison WC, Kedersha NL, Ariniello PD, Goldmacher VS, Lambert JM, Bl?ttler WA, Chari RV. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci U S A. 1996 Aug 06; 93(16):8618-23.

View in: PubMed

People

Explore

Similar Concepts

Top Journals